Antipsychotic pharmaceutical composition

Abstract

A pharmaceutical composition useful in treating psychosis contains a therapeutically effective amount of 2-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one as an active ingredient.

What is claimed is:  
     
         1 . An antipsychotic pharmaceutical composition comprising an antipsychosis therapeutically effective amount of 
 2-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one having the following formula or a pharmaceutically acceptable salt thereof, as an active ingredient, in combination with a pharmaceutically acceptable carrier or diluent for the active ingredient:                          wherein R 1  is C1-C6 alkylene, carbonyl, C1-C6 alkylene carbonyl or carbonyloxy; and R 2  is hydrogen, C1-C6 alkyl, C1-C6 alkoxy or halogen.    
     
     
         2 . The antipsychotic pharmaceutical composition according to  claim 1 , wherein R 1  is methylene or carbonyl.  
     
     
         3 . The antipsychotic pharmaceutical composition, wherein R 1  is carbonyl.  
     
     
         4 . The antipsychotic pharmaceutical composition according to  claim 1 , wherein R 2  is hydrogen or halogen.  
     
     
         5 . The antipsychotic pharmaceutical composition according to  claim 2 , wherein R 2  is hydrogen or halogen.  
     
     
         6 . The antipsychotic pharmaceutical composition according to  claim 3 , wherein R 2  is halogen.  
     
     
         7 . The antipsychotic pharmaceutical composition according to  claim 6 , wherein R 2  is fluorine.  
     
     
         8 . The antipsychotic pharmaceutical composition according to  claim 6 , which is orally administered.